Bayer Aktiengesellschaft (ETR:BAYN)
Germany · Delayed Price · Currency is EUR | Market Cap | 25.60B |
| Revenue (ttm) | 46.17B |
| Net Income (ttm) | -3.42B |
| Shares Out | 982.42M |
| EPS (ttm) | -3.48 |
| PE Ratio | n/a |
| Forward PE | 7.00 |
| Dividend | 0.11 (0.42%) |
| Ex-Dividend Date | Apr 28, 2025 |
| Volume | 1,363,201 |
| Average Volume | 1,739,981 |
| Open | 26.49 |
| Previous Close | 26.51 |
| Day's Range | 25.78 - 26.59 |
| 52-Week Range | 18.38 - 29.93 |
| Beta | 0.83 |
| RSI | 35.55 |
| Earnings Date | Nov 12, 2025 |
About Bayer Aktiengesellschaft
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skin... [Read more]
Financial Performance
In 2024, Bayer Aktiengesellschaft's revenue was 46.61 billion, a decrease of -2.16% compared to the previous year's 47.64 billion. Losses were -2.55 billion, -13.23% less than in 2023.
Financial StatementsNews
Bayer Hires Judith Hartmann as CFO in Latest Management Move
Bayer AG appointed Judith Hartmann as chief financial officer from June next year in the latest change to the struggling German company’s management team.
Dr. Judith Hartmann to Become New Chief Financial Officer of Bayer AG
LEVERKUSEN, Germany--(BUSINESS WIRE)--The Supervisory Board of Bayer AG has appointed Dr. Judith Hartmann to the company's Board of Management, effective March 1, 2026. She will succeed Wolfgang Nickl...
Bayer to Present New Data for KERENDIA® (finerenone) in People with Chronic Kidney Disease and Type 1 or Type 2 Diabetes at American Society of Nephrology (ASN) Kidney Week 2025
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that data from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented in scientific sessions at the American So...
Bayer's Monsanto must pay $185 million after Washington court restores chemical leak verdict
(Corrects year of trial in paragraph 2) By Diana Novak Jones (Reuters) -A U.S. court reinstated a $185 million verdict against Bayer's Monsanto unit over chemical contamination at a Washington state
Bayer and Luke Bryan Mark 10 Years of Fighting Hunger with YourUpdateTV
The ‘Take Care, Now' Campaign Has Helped Provide 10 Million Meals to Families in Need Through Feeding America The ‘Take Care, Now' Campaign Has Helped Provide 10 Million Meals to Families in Need Thro...
Bayer Wins FDA Approval for Menopause Drug Treating Hot Flashes
Bayer AG won support from US regulators for a menopause drug that’s expected to hit the market in November under the name of Lynkuet.
US FDA approves Bayer's menopause relief drug
Germany's Bayer said on Friday the U.S. Food and Drug Administration has approved its drug for menopause relief.
Bayer’s Lynkuet (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1) and n...
Bayer's Lynkuet® (elinzanetant), the First and Only Neurokinin 1 and Neurokinin 3 Receptor Antagonist, Receives FDA Approval for Moderate to Severe Hot Flashes Due to Menopause
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the U.S. Food and Drug Administration (FDA) has approved Lynkuet® (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted ...
Top 3 Health Care Stocks You'll Regret Missing In October
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go ...
Bayer Leverkusen vs PSG: Head-to-head, match preview, predicted lineups and score prediction
The UEFA Champions League is heating up, and all eyes are on the BayArena for a mouthwatering clash between Bayer...
BAYRY Begins Phase I Study With KQB548 in KRAS-Mutated Cancers
Bayer and Kumquat launch a phase I study of KQB548, aiming to target various KRAS G12D-mutated tumors like pancreatic, colorectal and lung cancer.
Why Bayer's Worst Years Might Be The Start Of Its Comeback
Bayer remains undervalued despite litigation and weak results, with upside if turnaround succeeds and FCF normalizes. Find out why BAYZF stock is a buy.
3 Large Drug Stocks to Watch as Industry Recovers After PFE-Trump Deal
Pfizer's landmark pricing deal with Trump sparks a pharma rally as J&J, Bayer and Novartis emerge as strong contenders for inclusion in one's portfolio.
Hesperos and Bayer Consumer Health Develop First Human-on-a-Chip® Model of Stress-Induced Cognitive Dysfunction
ORLANDO, Fla.--(BUSINESS WIRE)-- #BiotechNews--Hesperos, Inc. (Hesperos), a global leader focused on improving preclinical drug development, food, cosmetic, and chemical testing with its Human-on-a-Ch...
Bayer Partners with Cornfed Farms to Create First ForwardFarm in Midwest
ST. LOUIS--(BUSINESS WIRE)--Bayer is proud to announce that Cornfed Farms, a fourth-generation farm operated by the Mohr family, has been designated as the first Bayer ForwardFarm site in the Midwest ...
One A Day® Unveils Bold New Brand Identity and Platform: "The ONE for you"
One A Day®, the multivitamin and supplement brand by Bayer rooted in 80+ years of nutritional science, today announced a bold new brand identity and positioning designed to better connect with today's...
One A Day Unveils Bold New Brand Identity and Platform: “The ONE for you”
One A Day, the multivitamin and supplement brand by Bayer rooted in 80+ years of nutritional science, today announced a bold new brand identity and positioning designed to better connect with today’s ...
Luke Bryan and Bayer discuss the Take Care, Now campaign With YourUpdateTV
10 Years of Supporting Rural America: Bayer and Luke Bryan Team Up with Feeding America® to Tackle Hunger with “Take Care, Now” Campaign 10 Years of Supporting Rural America: Bayer and Luke Bryan Team...
IPG Wins Bayer’s $720M Global Consumer Health Account
Interpublic Group (IPG) has been named global creative, production, and media partner for Bayer’s Consumer Health division, leading marketing for brands including Aspirin, Claritin, and Alka-Seltzer, ...
Interpublic Group (IPG) Chosen by Bayer for Global Creative Partnership
Interpublic Group (IPG) Chosen by Bayer for Global Creative Partnership
Outrage mounts as Republicans in Congress move to protect pesticide makers from lawsuits
Bayer, maker of Roundup weedkiller, founded group pushing to block cancer claim suits against pesticide makers It’s been seven years since Germany ’s Bayer bought US agrochemical giant Monsanto , inhe...
Bayer Canada Announces New Distribution Partnership for ADALAT® XL® (nifedipine extended-release tablets) 30 mg Tablets in Canada
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Bayer Canada is pleased to announce a new partnership with Mint Pharmaceuticals Inc. for the distribution of ADALAT® XL® 30 mg tablets1 in Canada. This strategic...
Bayer to Highlight New Data for KERENDIA® (finerenone) at Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today that data from across the KERENDIA® (finerenone) comprehensive clinical trial program will be presented at the Heart Failure Society of America (...
Focus: Parkinson's disease at forefront of Bayer bet on cell and gene therapies
Bayer's pioneering cell and gene therapies for Parkinson's disease are at the forefront of an exciting but risky test of CEO Bill Anderson's development credentials as patent expiries on blockbuster d...